Trial Profile

VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VLX 1570 (Primary) ; Dexamethasone
Indications Multiple myeloma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Vivolux

Most Recent Events

03 Mar 2020 Results characterizing the safety, tolerability and pharmacokinetic Behavior VLX1570 published in the Investigational New Drugs
03 May 2018 Status changed from suspended to discontinued.
03 Oct 2017 This trial has been discontinued in Finland (End date: 2017-09-18).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com